Asymmetric and symmetric dimethylarginine in patients presenting with risk factors for coronary heart disease
Central European Journal of Medicine, 07/17/2012
Ilic MD et al. - Asymmetric dimethylarginine (ADMA) significantly correlated with symmetric dimethylarginine (SDMA) in ≥3 risk factor (RF), hypertensive, non-obese and non-diabetic patients, as well as in middle-aged and young controls.Methods
- Patients and methods: Overall, 113 participants were enrolled in the study, including 45 patients presenting with risk for CHD (27 male and 18 female; aged 55.9 ± 6.4 years), 30 sex and age-matched middle-aged healthy controls (16 male and 14 female; aged 56.3 ± 8.4 years), and 38 young healthy controls (38 male; aged 24.6 ± 3.9 years).
- No significant differences for ADMA and SDMA were recorded between patients groups presenting with risk for CHD.
- However, ADMA and SDMA were significantly higher in all examined patient groups (≥3 and 1–2 RF, hypertensive and non-hypertensive, obese and non-obese, diabetics and non-diabetics) compared with both control groups (middle-aged and young controls) (p<0.001).
- ADMA significantly correlated with SDMA in ≥3 RF (p<0.05), hypertensive (p<0.05), non-obese (p<0.05), non-diabetics (p<0.01), as well in middle-aged (p<0.05) and young controls (p<0.001).